Investigational drug · Phase 3
TAK-928
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IO Resistant Squamous and Nonsquamous NSCLC.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TAK-928"
First trial start
2025
Nov 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-928", any sponsor or status.
Conditions studied
As listed on its trial records.
- IO Resistant Squamous and Nonsquamous NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-928" as an intervention, largest first.
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07217301 · 1,200 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 1, 2028
Drug: TAK-928; Control Arm · For: IO Resistant Squamous and Nonsquamous NSCLC
Sites: Jonesboro, Arkansas; Fair Oaks, California; Fountain Valley, California · 50 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.